Archived articles

Vaccines

A doctor administers a vaccine to a masked woman

COVID-19

Why the suspended AstraZeneca trial is good news for vaccine safety

Published Sept 10, 2020

Emergency medicine specialist Lauren Sauer tells 'Bloomberg' that although the setback delays coronavirus vaccine development, the final product will be safer for the public / Bloomberg

Q+A

How close are we to a safe, effective vaccine?

Published Aug 11, 2020

Vaccine expert Ruth Karron answers important questions about the process for developing a COVID-19 vaccine

Daniel Polsky named to panel on equitable allocation of COVID-19 vaccines

Published July 31, 2020

Bloomberg Distinguished Professor with appointments in the Carey Business School and Bloomberg School of Public Health joins a panel of experts who will advise policymakers on the fair allocation of COVID-19 vaccines

Q+A

Taming COVID-19 requires urgent search for both vaccine and treatment

Published May 28, 2020

Johns Hopkins lecturer Bonnie Robeson, who led drug discovery and development during AIDS epidemic, shares why scientists should prioritize finding a suitable therapy for COVID-19 as well as a vaccine

Q+A

Coronavirus vaccine won't emerge overnight

Published April 16, 2020

Supriya Munshaw, an expert in the commercialization of early-stage technologies at the Johns Hopkins Carey Business School, discusses the process of developing a vaccine for COVID-19

Colorful image of virus emerging from cells

Q+A

What will it take to develop a vaccine?

Published March 26, 2020

Global health expert Ruth Karron discusses the work currently taking place at laboratories around the country to develop a vaccine for COVID-19

public health

How best to behead a mosquito

Published Fall 2019

Engineer Russell Taylor and a group of students design a device to make it easier for biotech company Sanaria to develop a malaria vaccine / Johns Hopkins Magazine

Study: Viruses are leading cause of pneumonia in children

Published June 27, 2019

PERCH study, led by researchers at the Bloomberg School of Public Health, highlights the need for new vaccines, especially for respiratory synctial virus